Physician

Amit K Nahata, M.D.

According to 2025 Medicare claims, Amit Nahata, M.D. (NPI: 1417928904) practices nephrology in the Weirton-Steubenville, WV-OH market, with the plurality of this provider's patient population coming from Jefferson, OH. This provider's primary affiliated billing organization is TRINITY WEST (NPI: 1043234677; TIN: 34-0875691) and primary practice location at 43952-2300. Nahata is affiliated with the ACO West Virginia (ACO ID: A3563), participating under the MSSP model.

Nahata's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 454 traditional Medicare patients, billed 1,406 HCPCS/CPT codes, and received $149,171 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 2,170 prescription claims across 416 beneficiaries totaling $287,764 in drug costs, led by Farxiga (Dapagliflozin Propanediol). 2019 DME data shows 33 claims. Open Payments data shows 29 records totaling $7,768. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $225,752 to $149,171. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	492	2,392	$225,752
2016	524	2,379	$236,023
2017	568	2,525	$251,375
2018	541	1,800	$194,464
2019	495	1,880	$198,872
2020	468	1,597	$172,677
2021	435	1,370	$170,035
2022	434	1,201	$139,342
2023	573	1,804	$221,056
2024	454	1,406	$149,171

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	301	2,931	$367,046
2016	354	3,302	$524,984
2017	379	3,595	$515,551
2018	390	3,182	$601,031
2019	376	2,988	$566,141
2020	344	2,669	$385,342
2021	355	2,582	$404,524
2022	354	2,287	$463,689
2023	380	1,896	$369,661
2024	416	2,170	$287,764

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	11	$207
2018	N/R	28	$630
2019	N/R	33	$519
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	109	142	$128
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	101	124	$121
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	123	335	$90
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	162	188	$79
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	127	143	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	129	5,460	$102,801
Jardiance	Empagliflozin	65	3,324	$64,466
Sevelamer Carbonate	Sevelamer Carbonate	94	3,708	$26,856
Veltassa	Patiromer Calcium Sorbitex	19	680	$17,108
Invokana	Canagliflozin	13	630	$11,933

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	29	$7,768	SCPHARMACEUTICALS INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Amit K. Nahata, M.D.?

Tedicare shows public-source Medicare data for Amit K. Nahata, M.D. (NPI 1417928904), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Amit K. Nahata, M.D. have ACO affiliation data?

Amit K. Nahata, M.D. is shown with ACO affiliation data for ACO West Virginia (MSSP, ACO ID A3563).

What billing organization is linked to Amit K. Nahata, M.D.?

Amit K. Nahata, M.D. is linked to TRINITY WEST (billing NPI 1043234677) in the available physician profile data.

Does Amit K. Nahata, M.D. have Open Payments data?

Amit K. Nahata, M.D. has 29 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.